VEGF-C Antibody (A-5): sc-74584

VEGF-C Antibody (A-5) is a mouse monoclonal IgM antibody that detects VEGF-C in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VEGF-C is a crucial member of the vascular endothelial growth factor family, primarily known for its role in lymphangiogenesis, the formation of lymphatic vessels, which is vital for maintaining fluid homeostasis and immune responses. VEGF-C is predominantly expressed in lymphatic endothelial cells and plays a significant role in promoting the growth and development of lymphatic vessels, which can be particularly important in the context of cancer metastasis, as VEGF-C facilitates the spread of tumor cells through the lymphatic system. Additionally, VEGF-C interacts with specific receptors, such as Flt-4 and Flk-1, which are essential for mediating biological effects. VEGF-C′s ability to induce lymphatic endothelial cell proliferation and migration underscores VEGF-C′s importance in both normal physiological processes and pathological conditions, making anti-VEGF-C antibody (A-5) an invaluable tool for researchers studying angiogenesis and lymphangiogenesis in various disease models.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VEGF-C Antibody (A-5) References:

1. Prognostic Significance of VEGF-C Expression in Patients with Breast Cancer: A Meta-Analysis.  |  Liang, B. and Li, Y. 2014. Iran J Public Health. 43: 128-35. PMID: 26060735
2. Smad4 Inhibits VEGF-A and VEGF-C Expressions via Enhancing Smad3 Phosphorylation in Colon Cancer.  |  Li, X., et al. 2017. Anat Rec (Hoboken). 300: 1560-1569. PMID: 28445620
3. VEGF-C in rectal cancer tissues promotes tumor invasion and metastasis.  |  Miao, H., et al. 2018. J BUON. 23: 42-47. PMID: 29552758
4. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.  |  Michaelsen, SR., et al. 2018. Neuro Oncol. 20: 1462-1474. PMID: 29939339
5. Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma.  |  Huang, C., et al. 2018. Am J Transl Res. 10: 2911-2919. PMID: 30323877
6. VEGF-C attenuates ischemia reperfusion injury of liver graft in rats.  |  Cheng, MX., et al. 2019. Transpl Immunol. 54: 59-64. PMID: 30771456
7. Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer.  |  Oplawski, M., et al. 2019. Curr Pharm Biotechnol. 20: 1004-1010. PMID: 31333122
8. VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis.  |  Dai, C., et al. 2019. Int J Med Sci. 16: 1397-1403. PMID: 31692815
9. ADSCs stimulated by VEGF-C alleviate intestinal inflammation via dual mechanisms of enhancing lymphatic drainage by a VEGF-C/VEGFR-3-dependent mechanism and inhibiting the NF-κB pathway by the secretome.  |  Zhang, L., et al. 2022. Stem Cell Res Ther. 13: 448. PMID: 36064450
10. Sinusoidal and lymphatic vessel growth is controlled by reciprocal VEGF-C-CDH5 inhibition.  |  Sung, DC., et al. 2022. Nat Cardiovasc Res. 1: 1006-1021. PMID: 36910472

The preferred VEGF-C antibody is VEGF-C Antibody (E-6): sc-374628.